Rate Video

ASCO 2020 | hypomethylating agents in AML

Amer Zeidan • 1 Jun 2020

Acute Myeloid Leukemia Leukemia Azacitidine Decitabine

Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, outlines the advantages and underuse of hypomethylating agents in acute myeloid leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Combining hypomethylating agents in AML

Amer Zeidan • 1 Jun 2020

Cereblon and GSPT1 degrader in refractory/relapsed AML

Amer Zeidan • 12 Jun 2020

Onvansertib with cytarabine or decitabine for R/R AML

Amer Zeidan • 27 Sep 2019

Result of venetoclax plus/minus azacitidine for R/R MDS

Amer Zeidan • 8 Dec 2019

Related Videos

Real-world findings of MRD by MFC in AML

Bruno Paiva • 24 Feb 2021

Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT

Muhammad Husnain • 17 Feb 2021

SIERRA trial updates: apamistamab in AML

Tania Jain • 12 Feb 2021

CAR-T vs. BiTEs in B-cell malignancies

Marion Subklewe • 11 Feb 2021